Stifel downgraded Cerevel Therapeutics (CERE) to Hold from Buy with a price target of $43, up from $42, after AbbVie (ABBV) said it will acquire all outstanding shares of Cerevel for $45 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- The biopharma stocks to own in 2024, according to Morgan Stanley
- Cerevel Therapeutics to host conference call
- Cerevel Therapeutics just downgraded at TD Cowen, here’s why
- Cerevel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next